Article Text

PDF

P6.006 Counting the Pennies: Rational Prescribing Within the Context of the National Chlamydia Screening Programme
  1. K M Turner1,
  2. P Horner1,
  3. I Vincent1,
  4. E Adams2,
  5. J Macleod1
  1. 1University of Bristol, Bristol, UK
  2. 2Aquarius Population Health, London, UK

Abstract

Background In 2010/11 the National Chlamydia Screening Programme diagnosed over 90,000 cases of chlamydia in England. The current BASHH guidelines recommend either Azithromycin or doxycycline. Concerns have been raised questioning the efficacy of Azithromycin in routine practise.

Aims The aim of our study was to analyse whether current prescribing is in line with the criteria for rational prescribing and to estimate the cost and efficacy implications of a change in prescribing practise.

Methods We searched for published data on clinical effectiveness (both in randomised controlled trials and in practise), cost, compliance, universal use, acceptability, antimicrobial resistance and safety profiles.

We developed a simple costing tool to estimate the potential cost implications of prescribing practise and clinical effectiveness on the total treatment cost and the cost per infection treated.

Findings Until 2012, Azithromycin cost £9.65 per 4-tab 250mg pack in comparison with £1.70 per 28 capsule 50mg pack (BNF 2011–12). The cost of Azithromycin is now £1.50. The most recent findings in practise have suggested that the clinical effectiveness of Doxycycline may be superior to Azithromycin.

Interpretation

In health economic terms, if Doxycycline is clinically superior and costs less than Azithromycin, then Doxycycline regimens dominate. This could have saved significant costs in 2011/12 (up to £500,000). Now the costs are broadly equivalent, providing that the cheaper form of Azithromycin is prescribed. Doxycycline is also a valid choice of therapy, and extended regimens of Azithromycin could now also be considered without being prohibitively expensive.

Policy recommendation

Within the context of treatment of asymptomatic, uncomplicated chlamydia diagnosed through screening, Azithromycin is likely to continue to be the drug of choice. The process for implementing changes to prescription should be made more streamlined and transparent, so that evidence can be more rapidly translated into cost-savings.

  • chlamydia
  • rational prescribing
  • treatment

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.